Prognostic factors and outcome measures after BRAF-directed targeted therapy of unresectable metastatic BRAFV600E colorectal cancer: a study cohort-level analysis
{{output}}
BRAFV600E mutation in metastatic colorectal cancer (mCRC) is associated with a poor prognosis. BRAFV600E inhibitors (BRAFi) plus EGFR inhibitors + / - MEK inhibitors regimens prolonged overall survival (OS), but prognosis remains heterogeneous and intermediate... ...
